Characterizing Novel Microparticle Encapsulated Drug Formulations – Part 2

As the demand for targeted and controlled release therapies continues to rise, microparticle encapsulated drugs emerge as increasingly desirable dosage forms among clinicians. In this second part of our series, we delve deeper into the intricate process of injectable formulation development, focusing on the crucial task of characterizing and understanding the release kinetics of these microparticles. Singota Solutions (Bloomington, Indiana CDMO) R&D Department, committed to innovation and excellence, has been at the forefront of developing a novel microparticle formulation for a large protein molecule. From the utilization of a small batch aseptic filler to the implementation of aseptic manufacturing solutions, every aspect of our approach is meticulously crafted to ensure the integrity and efficacy of the final product. Moreover, our dedication to cold chain pharmaceutical storage within a GMP compliant warehouse underscores our commitment to maintaining product stability and quality throughout its journey. Join us in the second portion of our series (read part 1 HERE), as we navigate the complexities of this intricate process, offering insights into the challenges and triumphs encountered along the path to delivering cutting-edge pharmaceutical solutions.